A NEW FORM OF ADVANCED WOUND THERAPY
Rogers Sciences has developed a new technology using photomodulation light therapy designed to provide a solution to diseases that currently have no effective therapy.
The company’s core product platform is Photodynamic Bandages, wearable medical devices that emit narrow band light 24 hours a day, 7 days a week. Our first commercial product harnesses Lumina24™ BLU Technology for chronic wounds and acute burns.
Lumina24™ BLU activates naturally occurring chromophores in bacteria, targeting foreign cells while preserving healthy human tissue.
LIMITS OF CONVENTIONAL THERAPY
Current treatments face serious challenges. In addition to drug side effects, the over prescription of pharmaceuticals has created drug resistant pathogens. These pose serious threats to patients’ safety and quality of life.
A Solution to MDROs
Lumina24™ BLU has been proven to be effective against multi-drug resistant organisms. Lumina24™ BLU is antimicrobial therapy without pharmaceuticals.
CANCER TREATMENT THROUGH LIGHT
Rogers Sciences has developed Lumina24™ RED, deployed with a tumor-sensitizing medication, for managing cutaneous metastases of breast cancer in a home-based setting.
The CLIPT Advantage
Rogers Sciences’ cancer treatment utilizes our patented Continuous Low-Irradiance Photodynamic Therapy (CLIPT) regimen, a lower dose of light delivered over extended periods for less trauma.
Ambulatory Cancer Therapy
RSI’s initial product, Lumina24™ RED, is a device-drug combination therapy using a photosensitizing agent to activate treatment. Lumina24™ RED uses continuous low-irradiance photodynamic therapy to target cutaneous breast cancer metastases.
Lumina24™ RED achieves the positive outcomes of traditional PDT without burning or scarring of healthy tissue by delivering the same amount of energy over a longer time period using low irradiance, photomodulated light waves.
Advanced Wound Care
Building upon RSI’s initial technology, Lumina24™ BLU entered the wound care space with wavelengths designed to provide antimicrobial therapy and improve wound healing. The Lumina24™ platform is scalable to provide optimal treatment for all sizes of acute burns and chronic wounds.
Lumina24™ BLU technology is a pharmaceutical free therapy targeting microbial colonization and multi-drug resistant organisms (MDROs) within the dressing of chronic wounds.
RSI is proud to partner with experts in their fields across the country, pioneering the applications of photomodulation light therapy. We have clinical trials running at several sites across the U.S.
Lumina24™ RED is in a phase II clinical trial at Massachusetts General Hospital and the Dana Farber Cancer institute.
The newest clinical trial is a safety and efficacy feasibility study for Lumina24 BLU technology, accruing patients in New England and the Mid-Atlantic region.
Sam Hill, CEO
Mr. Hill has over 20 years of experience in the field of bio-optical engineering and developing hybrid-modality illumination devices. Mr. Hill has an M.S. from MIT and an M.S. in Optical Engineering from the University of Arizona.